Quick Answer
Dyne Therapeutics, Inc. reported Stockholders Equity of $972.13 million for fiscal year 2025.
Dyne Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $972.13M | +54.3% |
| 2024 | $629.84M | +589.9% |
| 2023 | $91.29M | -63.8% |
| 2022 | $252.36M | -31.5% |
| 2021 | $368.20M | +7.5% |
| 2020 | $342.37M | +2339.2% |
| 2019 | $14.04M | +387.7% |
| 2018 | -$4.88M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $691.78M | -1.9% | +21.1% |
| June 30, 2025 | $571.45M | -26.3% | -14.6% |
| March 31, 2025 | $668.97M | +39.9% | +6.2% |
| December 31, 2024 | $629.84M | +589.9% | -10.7% |
| September 30, 2024 | $705.54M | +364.1% | -9.0% |
| June 30, 2024 | $775.19M | +274.7% | +62.2% |
| March 31, 2024 | $478.06M | +97.6% | +423.7% |
| December 31, 2023 | $91.29M | -63.8% | -40.0% |
- Dyne Therapeutics, Inc. showed an increase of +54.3% in Stockholders Equity compared to the prior fiscal year.
- Over the 2018–2025 period, Dyne Therapeutics, Inc.’s stockholders equity has grown by 20024.8% (from -$4.88 million to $972.13 million).
- The most recent figure is from Dyne Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: